<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585700</url>
  </required_header>
  <id_info>
    <org_study_id>TORLAK-100</org_study_id>
    <nct_id>NCT02585700</nct_id>
  </id_info>
  <brief_title>A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine</brief_title>
  <official_title>A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split, Inactivated Influenza Vaccine Produced by Torlak in Healthy Adult Volunteers in Serbia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Virology, Vaccines and Sera, Torlak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comac Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Virology, Vaccines and Sera, Torlak</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of
      participants to receive seasonal trivalent split, inactivated influenza vaccine (A/H1N1;
      A/H3N2 and B) or placebo (phosphate buffered saline). A total of 60 healthy male and female
      adults 18 through 45 years of age will be randomized to receive vaccine (30) or placebo (30).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, double blinded, randomized, placebo-controlled study. The study will be
      conducted at 1 site in Serbia. Sixty (60) healthy male and female adults, 18 to 45 years of
      age, will be enrolled into the trial. Subjects will be randomized 1:1 to one of two treatment
      allocations: 30 to vaccine, 30 to placebo. The study will utilize a &quot;randomized block design&quot;
      to assure a balance of 1:1 vaccine and placebo when all subjects are enrolled. The study will
      be double blinded, meaning the study subjects, investigators, and the sponsor will be unaware
      of the treatment allocated to each subject until the clinical trial database is declared
      final and locked. The study should take about 5 months to complete, with each subject
      involved for 3 months from the day of injection. The justification for the 3 month follow up,
      rather than 6 month follow up is that this is an inactivated vaccine that follows very
      standard manufacturing practices with standard antigens. The safety of inactivated influenza
      vaccines is well-established. Adding length to the follow up results in delays in future
      testing of the vaccine for licensure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Immediate Adverse Events</measure>
    <time_frame>30-minute post-vaccination period.</time_frame>
    <description>Number of subjects with observed immediate adverse events, including allergic reaction or anaphylaxis, following administration of the study product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With Solicited Local Reactogenicity</measure>
    <time_frame>7-day period (Days 0-6) post-vaccination.</time_frame>
    <description>Number of subjects reporting solicited local reactions (redness, swelling, induration, pain and tenderness) at the injection site post-vaccination with study vaccine or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With Solicited Systemic Reactogenicity</measure>
    <time_frame>7-day period (Days 0-6) post-vaccination.</time_frame>
    <description>Number of subjects reporting solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or Placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With Occurrence of Unsolicited Adverse Events</measure>
    <time_frame>Within 21 days post vaccination</time_frame>
    <description>These data are presented broadly as number per group for the study. Please see AE reporting section for more specific details on AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)</measure>
    <time_frame>Over the entire study period (Day 90).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Seroconverted Subjects Against 3 Strains of Influenza Vaccine.</measure>
    <time_frame>Day 21</time_frame>
    <description>Seroconversion is defined as a serum HAI titer meeting the following criteria:
pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1:40 or
pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 21.
The 3 influenza strains assessed were B/Massachusetts, H1/A/California and H3/A/Texas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine</measure>
    <time_frame>Day 0 and Day 21 post vaccination</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer ≥ 1:40. The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens</measure>
    <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
    <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rises (GMFRs) of Serum (HAI) Antibodies (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.</measure>
    <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
    <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens.</measure>
    <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rises (GMFRs) of MNT (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.</measure>
    <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
    <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:
NYMC BX-51B reassortant of B/Massachusetts/2/2012
X-181 reassortant of H1/A/California/7/2009
X-223A reassortant of H3/A/Texas/50/2012.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 mL of phosphate buffered saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine, split inactivated</intervention_name>
    <description>Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen`s eggs, and inactivated with beta-propiolactone.</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL of phosphate buffered saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female adult 18 through 45 years of age at the enrollment visit.

          -  Literate (by self-report) and willing to provide written informed consent.

          -  Healthy, as established by the medical history, physical examination, and screening
             laboratory evaluations.

          -  Capable and willing to complete Memory Aids and willing to return for all follow-up
             visits.

          -  For females, willing to utilize reliable birth control measures (e.g., intrauterine
             device, hormonal contraception, condoms) from Day 0 through the Day 21 visit.

        Exclusion Criteria:

          -  Participation in another clinical trial involving any therapy within the previous
             three months or planned enrollment in such a trial during the period of this study.

          -  Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to
             postpone receipt of such vaccines until after the Day 21 visit.

          -  Current or recent (within 2 weeks of vaccination) acute illness with or without fever.

          -  Receipt of immune globulin or other blood products within 3 months prior to study
             enrollment or planned receipt of such products prior to the Day 21 visit.

          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of
             immunosuppressants or other immune-modulating therapy within six months prior to study
             vaccination. (For corticosteroids, this means prednisone or equivalent, equal or more
             than 0.5 mg per kg per day; topical steroids are allowed.)

          -  History of asthma.

          -  Hypersensitivity after previous administration of any vaccine.

          -  Suspected or known hypersensitivity to any of the study vaccine components, including
             chicken or egg protein.

          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary,
             metabolic, neurologic, psychiatric or renal functional abnormality, as determined by
             medical history, physical examination or clinical laboratory screening tests, which in
             the opinion of the investigator, might interfere with the study objectives.

          -  History of any blood or solid organ cancer.

          -  History of thrombocytopenic purpura or known bleeding disorder.

          -  History of seizures.

          -  Known or suspected immunosuppressed or immunodeficient condition of any kind.

          -  Confirmed hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Known HIV infection (self-report).

          -  Known active tuberculosis or symptoms of active tuberculosis, regardless of cause
             (self-report).

          -  History of chronic alcohol abuse and/or illegal drug use.

          -  Pregnancy or lactation. (A negative pregnancy test will be required before
             administration of study product for all women of childbearing potential.)

          -  History of Guillain-Barré Syndrome

          -  Any condition that, in the opinion of the investigator, would increase the health risk
             to the subject if he/she participates in the study or would interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Stevanovic, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Infectious and Tropical Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <results_first_submitted>May 11, 2017</results_first_submitted>
  <results_first_submitted_qc>July 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2019</results_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grippe</keyword>
  <keyword>Human Flu</keyword>
  <keyword>Human influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All volunteers were recruited at the Clinical Center of Serbia, Belgrade, Serbia.</recruitment_details>
      <pre_assignment_details>66 people were screened for the study after signing consent. 6 subjects failed screening. A total of 60 subjects received vaccine or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine Group</title>
          <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>0.5 mL of phosphate buffered saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccine Group</title>
          <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>0.5 mL of phosphate buffered saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.00" spread="7.21"/>
                    <measurement group_id="B2" value="30.70" spread="6.14"/>
                    <measurement group_id="B3" value="30.85" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Immediate Adverse Events</title>
        <description>Number of subjects with observed immediate adverse events, including allergic reaction or anaphylaxis, following administration of the study product.</description>
        <time_frame>30-minute post-vaccination period.</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Immediate Adverse Events</title>
          <description>Number of subjects with observed immediate adverse events, including allergic reaction or anaphylaxis, following administration of the study product.</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With Solicited Local Reactogenicity</title>
        <description>Number of subjects reporting solicited local reactions (redness, swelling, induration, pain and tenderness) at the injection site post-vaccination with study vaccine or placebo</description>
        <time_frame>7-day period (Days 0-6) post-vaccination.</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Solicited Local Reactogenicity</title>
          <description>Number of subjects reporting solicited local reactions (redness, swelling, induration, pain and tenderness) at the injection site post-vaccination with study vaccine or placebo</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hardness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With Solicited Systemic Reactogenicity</title>
        <description>Number of subjects reporting solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or Placebo</description>
        <time_frame>7-day period (Days 0-6) post-vaccination.</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Solicited Systemic Reactogenicity</title>
          <description>Number of subjects reporting solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or Placebo</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature above 37 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With Occurrence of Unsolicited Adverse Events</title>
        <description>These data are presented broadly as number per group for the study. Please see AE reporting section for more specific details on AEs.</description>
        <time_frame>Within 21 days post vaccination</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Occurrence of Unsolicited Adverse Events</title>
          <description>These data are presented broadly as number per group for the study. Please see AE reporting section for more specific details on AEs.</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)</title>
        <time_frame>Over the entire study period (Day 90).</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)</title>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events (SAEs)--related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs--not related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Seroconverted Subjects Against 3 Strains of Influenza Vaccine.</title>
        <description>Seroconversion is defined as a serum HAI titer meeting the following criteria:
pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1:40 or
pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 21.
The 3 influenza strains assessed were B/Massachusetts, H1/A/California and H3/A/Texas</description>
        <time_frame>Day 21</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Seroconverted Subjects Against 3 Strains of Influenza Vaccine.</title>
          <description>Seroconversion is defined as a serum HAI titer meeting the following criteria:
pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥ 1:40 or
pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination measured on Day 21.
The 3 influenza strains assessed were B/Massachusetts, H1/A/California and H3/A/Texas</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion to H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion to H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion to B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer ≥ 1:40. The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
        <time_frame>Day 0 and Day 21 post vaccination</time_frame>
        <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine</title>
          <description>A seroprotected subject was defined as a vaccinated subject who had a serum Hemagluttination Inhibition (HAI) titer ≥ 1:40. The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
          <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens</title>
        <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
        <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
        <population>All vaccinated subjects with no major protocol violations who have valid post vaccination immunogenicity measures</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens</title>
          <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
          <population>All vaccinated subjects with no major protocol violations who have valid post vaccination immunogenicity measures</population>
          <units>Titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT to H1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.97" lower_limit="11.30" upper_limit="23.10"/>
                    <measurement group_id="O2" value="21.19" lower_limit="14.82" upper_limit="30.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H1 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295.14" lower_limit="240.10" upper_limit="362.80"/>
                    <measurement group_id="O2" value="22.32" lower_limit="15.72" upper_limit="31.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.75" lower_limit="25.88" upper_limit="55.07"/>
                    <measurement group_id="O2" value="41.41" lower_limit="28.02" upper_limit="61.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439.67" lower_limit="320.54" upper_limit="603.06"/>
                    <measurement group_id="O2" value="42.87" lower_limit="28.92" upper_limit="63.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.47" lower_limit="7.91" upper_limit="13.86"/>
                    <measurement group_id="O2" value="10.72" lower_limit="7.72" upper_limit="14.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.95" lower_limit="56.88" upper_limit="101.40"/>
                    <measurement group_id="O2" value="10.66" lower_limit="7.69" upper_limit="14.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rises (GMFRs) of Serum (HAI) Antibodies (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.</title>
        <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
        <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
        <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rises (GMFRs) of Serum (HAI) Antibodies (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.</title>
          <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
          <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
          <units>fold rise</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFR for H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.49" lower_limit="12.22" upper_limit="27.95"/>
                    <measurement group_id="O2" value="1.05" lower_limit="1.00" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.65" lower_limit="7.82" upper_limit="17.35"/>
                    <measurement group_id="O2" value="1.04" lower_limit=".99" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" lower_limit="5.53" upper_limit="9.52"/>
                    <measurement group_id="O2" value="0.99" lower_limit=".96" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens.</title>
        <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
        <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens.</title>
          <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
          <units>Titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT to H1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.06" lower_limit="18.61" upper_limit="31.11"/>
                    <measurement group_id="O2" value="31.75" lower_limit="24.06" upper_limit="41.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H1 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.12" lower_limit="164.95" upper_limit="270.22"/>
                    <measurement group_id="O2" value="40.00" lower_limit="30.47" upper_limit="52.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.02" lower_limit="12.74" upper_limit="25.51"/>
                    <measurement group_id="O2" value="19.77" lower_limit="15.11" upper_limit="25.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.53" lower_limit="87.82" upper_limit="179.45"/>
                    <measurement group_id="O2" value="24.34" lower_limit="18.39" upper_limit="32.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.93" lower_limit="59.21" upper_limit="110.61"/>
                    <measurement group_id="O2" value="70.45" lower_limit="48.06" upper_limit="103.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.28" lower_limit="278.78" upper_limit="393.68"/>
                    <measurement group_id="O2" value="105.56" lower_limit="75.73" upper_limit="147.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rises (GMFRs) of MNT (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.</title>
        <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
        <time_frame>Pre- (Day 0) and post-vaccination (Day 21)</time_frame>
        <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Group</title>
            <description>0.5 mL of influenza vaccine split, inactivated with 15 mcg of HA of B/Massachusetts, H1/A/California, and H3/A/Texas</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>0.5 mL of phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rises (GMFRs) of MNT (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.</title>
          <description>The 3 influenza strains assessed were B/Massachusetts, H1/A/California an d H3/A/Texas</description>
          <population>All vaccinated subjects who have valid post vaccination immunogenicity measures with no major protocol violations</population>
          <units>fold rise</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFR for H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" lower_limit="6.70" upper_limit="11.49"/>
                    <measurement group_id="O2" value="1.26" lower_limit="1.09" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.96" lower_limit="4.89" upper_limit="9.92"/>
                    <measurement group_id="O2" value="1.23" lower_limit="1.14" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" lower_limit="3.11" upper_limit="5.38"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.18" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccine Group</title>
          <description>0.5 mL of influenza vaccine, split, inactivated with 15 mcg of HA of each of 3 strains:
NYMC BX-51B reassortant of B/Massachusetts/2/2012
X-181 reassortant of H1/A/California/7/2009
X-223A reassortant of H3/A/Texas/50/2012.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>0.5 mL of phosphate buffered saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Unrelated to study products</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <description>Unrelated to study products</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Unrelated to study products</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <description>Unrelated to study product</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Unrelated to study products</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Goran Stevanovic</name_or_title>
      <organization>Clinical Center of Serbia—Clinic for Infectious and Tropical Diseases</organization>
      <phone>+381 64 1703059</phone>
      <email>goran_ste@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

